3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
11
Phase 1
10
Phase 1/2
7
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Recurrence
1
Neoplasms, Plasma Cell
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Leukemia, Myeloid, Acute
1
Hodgkin Disease
1
Interventions
Dexamethasone
168
Bortezomib
90
Lenalidomide
85
Thalidomide
44
daratumumab
43
pomalidomide
42
Melphalan
39
Cyclophosphamide
33
carfilzomib
29
Calcium Dobesilate
27
Prednisone
19
Doxorubicin
16
elotuzumab
14
Filgrastim
12
ixazomib
11
isatuximab
11
Vincristine
10
Peripheral Blood Stem Cell Transplantation
10
belantamab mafodotin
9
Granulocyte Colony-Stimulating Factor
9
Zoledronic Acid
8
selinexor
7
dexamethasone acetate
7
Epoetin Alfa
7
Etoposide
6
fludarabine
5
Cisplatin
5
Carmustine
5
Radiotherapy
4
Mycophenolic Acid
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Multiple Myeloma
×
Panobinostat
×
Clear all
NCT01023308
2020-03-17
PANORAMA-1
Novartis
Phase 3
Completed
767 enrolled
17 charts